New member | NeuroKyma
PROVIDER OF ADVANCED TECHNOLOGY FOR PREDICTIVE ANALYSIS ON CNS TRIALS DISEASES AT THE CROSSING OF E-HEALTH AND NEURO-IMAGING Our mission is... View Article
XENOTHERA signs a pre-order contract of its anti-COVID treatment with the French government
XENOTHERA announces the signature of a contract to reserve 30,000 unit doses of XAV-19 with the French Ministry of Health... View Article
GlioCure expands its know-how and technological offer to nanovectors
GlioCure SA, a biotechnology company specializing in neuro-oncology, announces the launch of Cure’nCaps Solutions (www.curencaps.com), a platfom for the formulation... View Article
OSE Immunotherapeutics Announces Dosing of the First Healthy Volunteer in Phase 1 Clinical Trial of its Multi-Variant Second-Generation COVID-19 Vaccine
First-in-human study evaluating CoVepiT, a multi-variant T cell COVID-19 vaccine for people at risk and vulnerable populations. CoVepiT is a... View Article
Valneva to Participate in the World’s First COVID-19 Vaccine Booster Trial in the UK
Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant... View Article
New member | Attonuclei
ATTONUCLEI took advantage of its 10 years of experience in functionalized Quantum Dots our company is a high-tech company whose... View Article
OSE Immunotherapeutics Announces €10.7 Million in Additional Public Funding, via Bpifrance, to Finance Further Development of CoVepiT, its Multi-Target and Multi-Variant COVID-19 Vaccine in Phase 1 Clinical Phase
CoVepiT is a SARS-CoV-2 vaccine activating T cell defences through CD8 T cell multiepitopes. CoVepiT epitopes* are selected from 11... View Article
Valneva Announces Closing of $107.6 million Global Offering
Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant... View Article
Valneva Announces the Pricing of its Initial Public Offering on Nasdaq
Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant... View Article
Clinical Study demonstrates promising results for Investigative ALS Treatment; InFlectis BioScience is planning phase 2 trial of Next-Generation Therapy
A new study shows indications that Amyotrophic Lateral Sclerosis (ALS) may be treated with small molecules targeting the Integrated Stress... View Article